$EARS has catalysts coming in 2017 Q4 and 2018 Q1 and Q4:
Phase 3 AM-111 HEALOS - for Acute inner ear hearing loss. Completion of enrollment announced June 5, 2017. Data due 4Q 2017.
Phase 1 AM-125, an intranasal formulation of betahistine for the treatment of Meniere's disease and other vestibular disorders. Goal is to start Phase 1 in Q4 2017.
Phase 3 AM-101 Keyzilen TACTT3 - for Acute inner ear tinnitus. Enrollment resumption announced January 26, 2017 with top-line data 1Q 2018.
Phase 3 AM-111 ASSENT - for Acute inner ear hearing loss. Data due 2H 2018.
$EARS needs some good data on HEALOS! They are clearly hedging with AM-125 in the same quarter. The good news is they are a penny stock bio with THREE Phase 3 trials underway. High risk, high reward.
Know What You Own. My posts should not be construed as investment advice.
FEATURED POET Announces Design Win and Collaboration with Foxconn Interconnect Technology for High-speed AI Systems • May 14, 2024 10:09 AM
FEATURED Element79 Gold Corp Reports Exceptionally High-Grade Results from Lucero • May 14, 2024 7:00 AM
VAYK Added New Manager for Expansion into $64 Billion Domestic Short-term Rental Market • VAYK • May 14, 2024 9:00 AM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM